From: HLA-E expression in cervical adenocarcinomas: association with improved long-term survival
 |  | HLA-E low | HLA-E high | P value |
---|---|---|---|---|
 |  | n (%) | n (%) |  |
Histology | SCC | 42 (53) | 37 (47) | 0.010 |
(n = 192) | ASC | 20 (53) | 18 (47) |  |
 | AC | 23 (31) | 52 (69) |  |
Tumour stage | FIGO I | 72 (44) | 93 (56) | 0.662 |
(n = 192) | FIGO II | 13 (48) | 14 (52) |  |
HPV | Negative | 7 (44) | 9 (56) | 0.965 |
(n = 192) | Positive | 78 (44) | 98 (56) |  |
HPV type specific | HPV 16 | 42 (43) | 56 (57) | 0.949 |
(n = 151) | HPV 18 | 23 (43) | 30 (57) |  |
Tumour size | <40 mm | 56 (45) | 69 (55) | 0.997 |
(n = 183) | > = 40 mm | 26 (45) | 32 (55) |  |
Infiltration depth | <15 mm | 47 (40) | 70 (60) | 0.112 |
(n = 186) | > = 15 mm | 36 (52) | 33 (48) |  |
LVSI | Negative | 32 (38) | 53 (62) | 0.045 |
(n = 174) | Positive | 47 (53) | 42 (47) |  |
Resection margins | Tumour free | 62 (42) | 86 (58) | 0.178 |
(n = 191) | Tumour positive | 23 (54) | 20 (47) |  |
Parametria involvement | Tumour free | 76 (43) | 100 (57) | 0.314 |
(n = 192) | Infiltrated | 9 (56) | 7 (44) |  |
Lymph nodes | Negative | 60 (43) | 81 (57) | 0.426 |
(n = 192) | Positive | 25 (49) | 26 (51) |  |
Adjuvant radiotherapy | No | 37 (39) | 59 (61) | 0.110 |
(n = 192) | Yes | 48 (50) | 48 (50) |  |